Trevena, Inc. announced the launch of the oliceridine (TRV130) Phase 3 clinical program with the enrollment of patients in the open label Phase 3 ATHENA-1 study. This study will evaluate the safety and tolerability of oliceridine in patients with acute moderate-to-severe pain in a variety of clinical settings. ATHENA-1 is a Phase 3 open label, multicenter study evaluating the safety and tolerability of oliceridine in approximately 900 patients.

The study will enroll eligible patients with moderate to severe pain caused by medical conditions or surgery. Patients will be treated with oliceridine on an as-needed basis via IV bolus, patient-controlled analgesia (PCA) administration, or both, as determined by the investigator. The primary objective is to assess the safety and tolerability of oliceridine.

Pain intensity will be measured as a secondary endpoint. The Company also announced that an End-of-Phase 2 meeting with FDA has been scheduled for later this quarter. In the second quarter, the Company expects to communicate additional details of its Phase 3 development program, including details of its pivotal studies of oliceridine in acute moderate-to-severe pain.